This inventor holds 4 USPTO granted patents and 4 published patent applications and 4 EPO patents. Top assignees: Hoffmann-La Roche Inc., Roche Innovation Center Copenhagen A/s. Active years: 2020-2022.
Company Filing History:
2 out of 5,011 
2 out of 46 
Years Active: 2020-2022
Title: Annie Moisan: Innovator in Nephrotoxicity Screening
Introduction
Annie Moisan is a prominent inventor based in Basel, Switzerland. She has made significant contributions to the field of nephrotoxicity screening, holding a total of 4 patents. Her work focuses on developing methods to predict the nephrotoxic effects of nucleic acid molecules, which is crucial for drug development and safety assessment.
Latest Patents
Annie's latest patents include innovative methods for in vitro nephrotoxicity screening assays. One of her inventions relates to predicting the in vivo nephrotoxicity of a nucleic acid molecule, such as siRNA or antisense oligonucleotides, using an in vitro cell-based assay. This assay measures the levels of EGFR as a toxicity biomarker, potentially in combination with other biomarkers like ATP and KIM-1. Another patent focuses on predicting the nephrotoxicity of drug substances, again utilizing an in vitro cell-based assay that measures extracellular EGF levels as a toxicity biomarker.
Career Highlights
Throughout her career, Annie Moisan has worked with notable companies, including Hoffmann-La Roche Inc. and Roche Innovation Center Copenhagen A/S. Her expertise in nephrotoxicity screening has positioned her as a valuable asset in the pharmaceutical industry.
Collaborations
Annie has collaborated with esteemed colleagues such as Marcel Gubler and Sabine Sewing, contributing to advancements in her field.
Conclusion
Annie Moisan's innovative work in nephrotoxicity screening has made her a key figure in the development of safer therapeutic agents. Her contributions continue to impact the pharmaceutical industry positively.